약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 2.

Table. 2.

Characteristics of reports on warfarin, statin, concomitant and all other drugs

Characteristics Warfarin only (N=4,203) Statin only (N=24,365) Concomitant (N=648) All other drugs (N=927,856) p-value
N % N % N % N %
Sex <.0001
Male 2,215 (52.70) 11,508 (47.23) 349 (53.86) 371,650 (40.05)
Female 1,988 (47.30) 12,857 (52.77) 299 (46.14) 556,206 (59.95)
Age <.0001
0-19 18 (0.43) 44 (0.18) 0 (0.00) 48,529 (5.23)
20-39 133 (3.16) 649 (2.66) 10 (1.54) 148,332 (15.99)
40-64 1,338 (31.83) 11,882 (48.77) 195 (30.09) 433,816 (46.75)
65 2,714 (64.57) 11,790 (48.39) 443 (68.36) 297,179 (32.03)
Year <.0001
2016 1,086 (25.84) 4,429 (18.18) 205 (31.64) 169,722 (18.29)
2017 1,091 (25.96) 5,563 (22.83) 77 (11.88) 190,002 (20.48)
2018 929 (22.10) 4,765 (19.56) 261 (40.28) 186,247 (20.07)
2019 731 (17.39) 4,323 (17.74) 41 (6.33) 193,025 (20.80)
2020 366 (8.71) 5,285 (21.69) 64 (9.88) 188,860 (20.35)
Report type <.0001
Spontaneous report 3,481 (82.82) 10,347 (42.47) 93 (14.35) 848,090 (91.40)
Research (including PMS) 673 (16.01) 13,894 (57.02) 551 (85.03) 60,983 (6.57)
Literature 39 (0.93) 101 (0.41) 4 (0.62) 5,653 (0.61)
Unkwon 0 (0.00) 0 (0.00) 0 (0.00) 4 (0.00)
Others 10 (0.24) 23 (0.09) 0 (0.00) 13,126 (1.41)
Original reporter <.0001
Healthcare professionals1) 3,550 (84.46) 22,142 (90.88) 602 (92.90) 858,472 (92.52)
Consumers 138 (3.28) 348 (1.43) 7 (1.08) 34,222 (3.69)
Others2) 483 (11.49) 85 (0.35) 2 (0.31) 21,812 (2.35)
Unknown 32 (0.76) 1,790 (7.35) 37 (5.71) 13,350 (1.44)
Reporter <.0001
Regional harmpacovigilance centers 3,436 (81.75) 9,891 (40.60) 88 (13.58) 788,594 (84.99)
Manufacturer 733 (17.44) 14,327 (58.80) 559 (86.27) 101,590 (10.95)
Medical titutiionns 32 (0.76) 109 (0.45) 1 (0.15) 32,859 (3.54)
Pharmacy 0 (0.00) 1 (0.00) 0 (0.00) 38 (0.00)
Public health enter 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.00)
Consumer 1 (0.02) 26 (0.11) 0 (0.00) 2,152 (0.23)
Others 1 (0.002) 11 (0.05) 0 (0.00) 2,622 (0.28)
Serious adverse event <.0001
Yes 543 (12.92) 3,752 (15.40) 104 (16.05) 55,351 (5.97)
No 3,660 (87.08) 20,613 (84.60) 544 (83.95) 872,505 (94.03)

1)Including doctors, pharmacists and nurses; 2)Others, including attorneys and other medical professionals.

PMS: post-marketing surveillance.

Yakhak Hoeji 2023;67:15-22 https://doi.org/10.17480/psk.2023.67.1.15
© 2023 Yakhak Hoeji